{"Clinical Trial ID": "NCT00577122", "Intervention": ["INTERVENTION 1:", "Cohort I: MPA-Alone", "Medroxyprogesterone (MPA) progesterone acetate is given orally as a single daily dose.", "INTERVENTION 2:", "Cohort 2: MPA+IdoCM", "Medroxyprogesterone (MPA) progesterone acetate is given orally as a single daily dose.", "cyclophosphamide should be administered orally as a single daily dose. Methotrexate should be administered twice daily on days 1 and 2 of each week."], "Eligibility": ["Incorporation criteria:", "A breast adenocarcinoma confirmed histologically or cytologically with locally recidivating or metastatic measurable disease", "The primary tumour should be negative ER and negative PR", "Patients should be menopausal", "Patients may have received up to 3 previous chemotherapys for recurrent/metastatic disease.", "A suitable organ function, as demonstrated by the laboratory studies described in section 3.6 of the protocol", "Patients treated, asymptomatic brain metastases are eligible provided that treatment with chronic steroids is not necessary", "- Exclusion criteria:", "Patients should not have pleural effusion or extensive ascites.", "Patients should not have a history of DVT or pulmonary embolism", "Patients should not have received chemotherapy or hormonal treatment within 2 weeks of entry into the study.", "Patients should not have undergone radiation therapy within one week of entry into the study."], "Results": ["Performance measures:", "* Clinical benefit rate (CR + PR + SD > 6 months).", "To determine the clinical benefit rate (Full response + Partial response + Stable disease > 6 months) by response Assessment criteria in solid tumours (RECIST version 1.0). MPA monotherapy and MPA + low-dose oral cyclophosphamide and methotrexate (ldoCM) in patients with negative metastatic breast cancer of refractory hormone receptors.", "Time limit: basic until the end of the study, up to 3 years", "Results 1:", "Title of the arm/group: Cohort I: MPA-Alone", "- Arm/group description: Medroxyprogesterone acetate (AMP) is given orally as a single daily dose.", "Total number of participants analysed: 14", "Type of measurement: Number", "Unit of measure: Percentage of participants 7.1 (0.2 to 33.9)", "Results 2:", "Title of the arm/group: Cohort 2: MPA+IdoCM", "- Arm/group description: Medroxyprogesterone acetate (AMP) is given orally as a single daily dose.", "cyclophosphamide should be administered orally as a single daily dose. Methotrexate should be administered twice daily on days 1 and 2 of each week.", "Total number of participants analysed: 16", "Type of measurement: Number", "Unit of measure: Percentage of participants 6.3 (0.2-30.2)"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/14 (14.29 per cent)", "DEHYDRATION *0/14 (0.00 %)", "*1/14 (7.14 per cent)", "RENAL FAITH *0/14 (0.00%)", "DYSPNEA (BREAKDOWN DEVELOPMENT) *0/14 (0.00 %)", "AssPIRATION *0/14 (0.00 %)", "HYPOXIA *0/14 (0.00 %)", "PNEUMOTHORAX *1/14 (7.14 %)", "Adverse Events 2:", "Total: 2/16 (12.50 per cent)", "DEHYDRATION *1/16 (6.25 per cent)", "*0/16 (0.00 %)", "RENAL FAITH *1/16 (6.25 per cent)", "DYSPNEA (BREAKDOWN DEVELOPMENT) *2/16 (12.50%)", "ASSPIRATION *1/16 (6.25 per cent)", "HYPOXIA *1/16 (6.25 per cent)", "PNEUMOTHORAX *0/16 (0.00 %)"]}